Ann Hepatobiliary Pancreat Surg.  2024 May;28(2):144-154. 10.14701/ahbps.23-136.

Associations between income and survival in cholangiocarcinoma: A comprehensive subtype-based analysis

• Geng CX
• Gudur AR
• Kadiyala J
• Strand DS
• Shami VM
• Wang AY
• Podboy A
• Le TM
• Reilley M
• Zaydfudim V
• Buerlein RCD

• KMID: 2555927
• DOI: http://doi.org/10.14701/ahbps.23-136

Abstract

Backgrounds/Aims
Socioeconomic determinants of health are incompletely characterized in cholangiocarcinoma (CCA). We assessed how socioeconomic status influences initial treatment decisions and survival outcomes in patients with CCA, additionally performing multiple sub-analyses based on anatomic location of the primary tumor.
Methods
Observational study using the 2018 submission of the Surveillance, Epidemiology, and End Results (SEER)-18 Database. In total, 5,476 patients from 2004−2015 with a CCA were separated based on median household income (MHI) into low income (< 25th percentile of MHI) and high income (> 25th percentile of MHI) groups. Seventy-three percent of patients had complete follow up data, and were included in survival analyses. Survival and treatment outcomes were calculated using R-studio.
Results
When all cases of CCA were included, the high-income group was more likely than the low-income to receive surgery, chemotherapy, and local tumor destruction modalities. Initial treatment modality based on income differed significantly between tumor locations. Patients of lower income had higher overall and cancer-specific mortality at 2 and 5 years. Non-cancer mortality was similar between the groups. Survival differences identified in the overall cohort were maintained in the intrahepatic CCA subgroup. No differences between income groups were noted in cancer-specific or overall mortality for perihilar tumors, with variable differences in the distal cohort.
Conclusions
Lower income was associated with higher rates of cancer-specific mortality and lower rates of surgical resection in CCA. There were significant differences in treatment selection and outcomes between intrahepatic, perihilar, and distal tumors. Population-based strategies aimed at identifying possible etiologies for these disparities are paramount to improving patient outcomes.

Keyword

Social determinants of health; Cholangiocarcinoma

Figure

• 

  Fig. 1 Kaplan–Meier model of overall mortality based on income for all tumors. p-value (log-rank) = 3e−7.

Reference

References

1. Gad MM, Saad AM, Faisaluddin M, Gaman MA, Ruhban IA, Jazieh KA, et al. 2020; Epidemiology of cholangiocarcinoma; United States incidence and mortality trends. Clin Res Hepatol Gastroenterol. 44:885–893. DOI: 10.1016/j.clinre.2020.03.024. PMID: 32359831.

2. Patel N, Benipal B. Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states. Cureus. 2019; 11:e3962. DOI: 10.7759/cureus.3962.

3. Rizvi S, Gores GJ. 2013; Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. DOI: 10.1053/j.gastro.2013.10.013. PMID: 24140396. PMCID: PMC3862291.

4. Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. 2019; Surgery for cholangiocarcinoma. Liver Int. 39 Suppl 1:143–155. DOI: 10.1111/liv.14089. PMID: 30843343. PMCID: PMC6563077.

5. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. 2021; Cholangiocarcinoma. Nat Rev Dis Primers. 7:65. DOI: 10.1038/s41572-021-00300-2. PMID: 34504109. PMCID: PMC9246479.

6. Uppal DS, Wang AY. 2015; Advances in endoscopic retrograde cholangiopancreatography for the treatment of cholangiocarcinoma. World J Gastrointest Endosc. 7:675–687. DOI: 10.4253/wjge.v7.i7.675. PMID: 26140095. PMCID: PMC4482827.

7. Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017; 2017:2819372. DOI: 10.1155/2017/2819372. PMID: 28408935. PMCID: PMC5376950.

8. Geng CX, Gudur AR, Radlinski M, Buerlein RCD, Strand DS, Sauer BG, et al. 2023; Socioeconomic disparities affect outcomes in early-stage esophageal adenocarcinoma: a SEER analysis. Clin Gastroenterol Hepatol. 21:2797–2806.e6. DOI: 10.1016/j.cgh.2023.02.011. PMID: 36858145.

9. Zhu MX, Li Y. 2020; The correlations between socioeconomic status and intrahepatic cholangiocarcinoma in the United States: a population-based study. Transl Cancer Res. 9:4931–4942. DOI: 10.21037/tcr-20-2506. PMID: 35117855. PMCID: PMC8798916.

10. National Cancer Institute. Static county attributes [Internet]. NIH;2022. cited 2022 Jul 11. Available from: https://seer.cancer.gov/seerstat/variables/countyattribs/static.html-:~:text=The%20static%20county%20attributes%20are,populations%20from%20survey%20sample%20data.

11. Woods LM, Rachet B, Coleman MP. 2006; Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 17:5–19. DOI: 10.1093/annonc/mdj007. PMID: 16143594.

12. Wrigley H, Roderick P, George S, Smith J, Mullee M, Goddard J. 2003; Inequalities in survival from colorectal cancer: a comparison of the impact of deprivation, treatment, and host factors on observed and cause specific survival. J Epidemiol Community Health. 57:301–309. DOI: 10.1136/jech.57.4.301. PMID: 12646548. PMCID: PMC1732424.

13. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ. Scottish Cancer Therapy Network. 2001; Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health. 55:308–315. DOI: 10.1136/jech.55.5.308. PMID: 11297648. PMCID: PMC1731899.

14. Zullig LL, Jackson GL, Provenzale D, Griffin JM, Phelan S, van Ryn M. 2012; Transportation: a vehicle or roadblock to cancer care for VA patients with colorectal cancer? Clin Colorectal Cancer. 11:60–65. DOI: 10.1016/j.clcc.2011.05.001. PMID: 21803001. PMCID: PMC3274660.

15. Lee RM, Liu Y, Gamboa AC, Zaidi MY, Kooby DA, Shah MM, et al. 2019; Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: what is driving disparities in receipt of treatment? J Surg Oncol. 120:611–623. DOI: 10.1002/jso.25632. PMID: 31301148. PMCID: PMC6752195.

16. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. 2006; Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 98:873–875. DOI: 10.1093/jnci/djj234. PMID: 16788161.

17. Walter D, Ferstl P, Waidmann O, Trojan J, Hartmann S, Schnitzbauer AA, et al. 2019; Cholangiocarcinoma in Germany: epidemiologic trends and impact of misclassification. Liver Int. 39:316–323. DOI: 10.1111/liv.13954. PMID: 30176117.

18. Khan SA, Emadossadaty S, Ladep NG, homas HC, Elliott P, Taylor-Robinson SD, et al. 2012; Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 56:848–854. DOI: 10.1016/j.jhep.2011.11.015. PMID: 22173164.

19. Khan SA, Tavolari S, Brandi G. 2019; Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 39 Suppl 1:19–31. DOI: 10.1111/liv.14095. PMID: 30851228.